Saurabh, Founder and Managing Partner, provides forward thinking financial planning and forecasting support and an entrepreneurial approach to creating and assessing financial strategies to the CEO of young biotech/medtech companies. Saurabh is passionate about valuation and corporate finance and his expertise lies in valuing early stage companies and products that has several uncertainties involved in the life cycle.
Having worked with several young life sciences companies in the areas of finance, he provides a strong financial perspective to the strategic decisions taken by the board and intends to position himself as a Value Integrator to the CEO to drive long term growth of his clients. Besides, his areas of interest include Real Options and Decision trees framework that captures the management’s flexibility in the times of uncertainty. He has developed strong interest towards market cycles that he uses to advice clients that plans to go IPO or raise money.
He is a frequent speaker on early stage valuation at several life sciences forums and associations.
His rich international experience includes engagements across India, the USA, Southern Europe and Nordic countries. In addition, he is an Independent expert at European Commission where he evaluates Horizon 2020 proposals.
He has an MBA from ESADE Business School and Bsc. Engineering from BIT Sindri, India. Saurabh is a voracious reader and has strong interest in gourmet cooking when he is not busy at work.
Ramon is a scientist cum entrepreneur who brings to Farmantra, 28 years of valuable experience in biopharmaceutical industry. He started his own venture in Diagnostics in 1984 and sold his company to Leti Laboratories in 2008. He was awarded by Barcelona Activa for his contribution to the development of synergies between the Industry and University in 2006. He was also a member of Spanish steering committee of Health Ministry for Toxic Oil Syndrome in 1985.
Besides his technical skills, he developed his sales and marketing acumen by working as Sales and Marketing manager in different biopharmaceutical companies.
Ramon is a PhD in Biochemistry and Molecular Biology from Universidad Autonoma de Madrid.
Dr. Xavier Luria
Dr. Xavier Luria is the Chair and Senior Consultant at DDR Drug Development and Regulation based in Barcelona and London. He was Head of Safety and Efficacy of Medicines at the European Medicines Agency (EMA) during 2005-2012, and previously held leadership positions in the biopharmaceutical industry for more than eighteen years, covering international clinical development, pharmacovigilance, biostatistics and medical affairs.
In addition to Dr. Luria’s specialty in internal medicine, pharmaceutical medicine and biostatistics (University Autonomous Barcelona), he has developed expertise in several specific therapeutic areas, carried out postgraduate qualification in clinical pharmacology, drug development and regulation (Tufts University School of Medicine, Boston), he is a recognized expert on regulatory systems and benefit-risk assessment (modelling, development and methodologies) and has been lecturer at the UCSF.
Furthermore, he is consultant for governments in Europe and Latin America and professor of Regulation of Life Science Industry at the IE Business School and lecturer at several other academic institutions in Europe and USA. He is currently member of the Kinesys Advisory Board, scientific and regulatory advisor at TFS, Premier Expert Consultant at NDA Partners , Senior Advisor and UK representative of SFL, and he is also member of the European Advisory Board of RAPS
At Farmantra, Dr. Luria collaborates on evaluating regulatory risks of the products during valuation of the products/technologies.
Kevin McAllister is the Managing Director of Neurenable GmbH, a company enabling Neuroscience research and development by offering advisory, strategic, and due diligence services to entrepreneurs, venture capital, pharma and non-profit organisations. Kevin also serves as strategic advisor or as an Advisory board member to biotech and data-science start-ups and financial services companies. Prior to this he was Executive Director in the Neuroscience Disease Area, Novartis Institutes for Biomedical Research, and Principal Medical Scientific Expert in the Novartis Neuroscience Clinical Development Franchise. Kevin holds a PhD from the University of Wales, UK, and an MBA from the International Institute for Management Development, Lausanne, Switzerland.
In a career spanning over 20 years in Pharmaceutical industry, Animesh had undertaken various key responsibilities in senior positions at large pharmaceutical companies like BASF corporation, Roche, GSK and AstraZeneca. He is the founder and President of Propharmance, LLC. He is currently at Propharmance supporting and advising clients like Astellas Pharma, J&J, AstraZeneca, Genentech and others on various BD, Marketing Research and Commercial Analytic projects on both long-term and short-term engagement basis.
In his previous roles like Senior BD&L Finance Manager – Strategic Partnering and Business Development, he played pivotal role in major deals worth more than $3.5 billion in total in the USA and other global markets(in-licensing, divestments, OTC deals, authorized generics, acquisitions, collaboration, co-development, co-marketing, early stage, late stage assets across various therapeutic areas – small and large molecules & technology platforms).
Animesh did his PhD (CNS Pharmacology) from the University of Georgia, Georgia, USA and MBA (Information Systems) from Bowling Green State University, Ohio, USA.